Although combining anti‐IL‐1β or anti‐IL‐1R therapies with ICIs may enhance anti‐tumour immunity,152 the phase III trial of the IL‐1β inhibitor canakinumab plus pembrolizumab for first‐line advanced/metastatic NSCLC failed to show a significant survival benefit (NCT03631199),153 highlighting the need for validation in other tumour types. The gene discussed is IL1B; the disease is non-small cell lung carcinoma.